This study investigated the relationship between Matrix Metalloproteinase-2 (MMP-2) and Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) gene polymorphisms and acne pathogenesis. The study aimed to determine whether specific genotypes (MMP-2-CC and TIMP-2-CC) are associated with impaired skin barrier function (measured by transepidermal water loss and skin hydration) and elevated levels of inflammatory cytokines (IL-1β, TNF-α) in acne patients compared to healthy controls.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Genotype Frequencies of MMP-2 and TIMP-2
Timeframe: Data for each participant were collected at a single visit during the study period from March 2018 to September 2021.
Skin Barrier Function Assessment
Timeframe: Data for each participant were collected at a single visit during the study period from March 2018 to September 2021.
Serum Interleukin-1β (IL-1β) Level
Timeframe: Data for each participant were collected at a single visit during the study period from March 2018 to September 2021.
Serum Tumor Necrosis Factor-α (TNF-α) Level
Timeframe: Data for each participant were collected at a single visit during the study period from March 2018 to September 2021.